You are here

  • Home
  • Online First
  • Optimising adalimumab administration to improve patient experience and treatment adherence in immune-mediated inflammatory diseases

Article Text

Article menu
Download PDFPDF
Letter
Optimising adalimumab administration to improve patient experience and treatment adherence in immune-mediated inflammatory diseases
  1. Aron Misa Garcia,
  2. Sara Ferro Rodríguez
    1. Pharmacy, SERGAS, Santiago de Compostela, A Coruña, Spain
    1. Correspondence to Dr Aron Misa Garcia, SERGAS, Santiago de Compostela, Spain; aronmisagarcia{at}gmail.com

    https://doi.org/10.1136/ejhpharm-2024-004229

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      Immune-mediated inflammatory diseases (IMIDs) are a group of pathologies characterised by acute or chronic inflammation that can affect a multitude of organs such as the skin, joints or digestive tract.1 Their prevalence in Western society is between 5% and 7%.2

      This group of diseases shares a common pathophysiology characterised by an imbalance in inflammatory cytokines.1 Of all the cytokines involved, tumour necrosis factor-α (TNF-α) was the first to be investigated and the origin of the first group of specific …

      View Full Text

      Footnotes

      • Collaborators not applicable.

      • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

      • Competing interests None declared.

      • Provenance and peer review Not commissioned; internally peer reviewed.